Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication
Executive Summary
New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.
You may also be interested in...
Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data
Two weeks after obtaining its third cancer indication and the same day Kite CEO Christi Shaw’s departure was announced, Gilead’s antibody-drug conjugate yielded Phase II data it says will help toward full approval in urothelial cancer.
Autolus Taps Markets After CAR-T Success In Pivotal Leukemia Trial
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.
Kite Wins EMA Recommendation To Market Tecartus For Leukemia Patients
The European Medicines Agency has recommended new uses for six approved products, including the CAR T-cell therapy Tecartus.